Breast cancer susceptibility gene BRCA1 has been implicated in the control of gene regulation and such regulated genes are thought to mediate the biological role of BRCA1. Overexpression of BRCA1 induces GADD45, a p53-regulated and stress-inducible gene. However, the molecular mechanism by which BRCA1 induces the expression GADD45 remains unclear. In this report, we have shown that the GADD45 promoter is strongly activated following expression of wild-type BRCA1. In contrast, both the tumor-derived BRCA1 mutants (p1749R and Y1853insA) and truncated BRCA1 mutant protein (D500 ± 1863 BRCA1), which lack transactivation activity, were unable to activate the GADD45 promoter, indicating that the BRCA1-mediated activation of the GADD45 promoter requires normal transcriptional properties of BRCA1. BRCA1 did not induce the c-Jun and c-fos promoters, which rules out a general eect of BRCA1 on other immediateresponsive genes. Expression of the human papillomavirus E6 and the dominant-negative mutant p53 proteins had no eect on the induction of the GADD45 promoter by BRCA1, suggesting that activation of the GADD45 promoter by BRCA1 is independent of cellular p53 function. With the 5'-deletion analysis, the BRCA1-responsive element of the GADD45 promoter was mapped at the region from 7121 to 775. Disruption of this region resulted in the abrogation of BRCA1 activation of the GADD45 promoter. Taken together, these results demonstrate that the mechanism by which BRCA1 induces GADD45 is mainly through the transactivation of the GADD45 promoter, further demonstrating the evidence that GADD45 acts as one of the BRCA1-regulated genes. Oncogene (2000) 19, 4050 ± 4057.
Introduction
Breast cancer is the most frequent malignancy in women. More than half of the hereditary breast cancer can be attributed to mutations in the breast cancer susceptibility gene BRCA1, Ford and Easton, 1995; Miki et al., 1994) . Human BRCA1 encodes an 1863 amino acid nuclear phosphoprotein (Miki et al., 1994) that is expressed in a variety of human tissues (Marquis et al., 1995) . BRCA1 levels are cell cycle-dependent, with peak levels at the G1/S border and low levels in late S or G2 (Rajan et al., 1996; Vaughn et al., 1996) . Normally, BRCA1 associates and colocalizes with Rad51, the human homologue of the Escherichia coli RecA protein, and may be involved in the process of DNA recombination. Following exposure to DNA damage, BRCA1 becomes hyperphosphorylated and then dynamically redistributes to the complexes containing proliferating cell nuclear antigen (PCNA), suggesting that BRCA1 may participate in a replication checkpoint response (Scully et al., 1997) . It has also been found that BRCA1 plays an important role in the transcription-coupled repair of DNA damage (Gowen et al., 1998) . Several lines of evidence demonstrate that BRCA1 plays an important role in the control of cell cycle progression. Introduction of the COOH terminus of BRCA1 (residues 1293 ± 1863), which behaves in a dominant-negative manner, into nontumorigenic human breast epithelial cells can cause a reduction in the doubling time and abrogation of the G2-M block induced by the spindle inhibitor colchicine (Larson et al., 1997) . Additionally, Murine embryos carrying a BRCA1 null mutation exhibit hypersensitivity to DNA damage and chromosomal abnormalities (Shen et al., 1998) . Disruption of endogenous BRCA1 protein through introducing antisense oligonucleotides to BRCA1 mRNA accelerated the growth of normal and malignant mammary cells (Thompson et al., 1995) . Similarly, NIH3T3 cells with a stable expression of antisense BRCA1 mRNA displayed an accelerated growth rate and tumorigenesis in nude mice (Rao et al., 1996) . In addition, introduction of wild-type BRCA1 into cells resulted in the growth suppression in both breast and ovarian tumor lines (Holt et al., 1996) .
A number of observations have implicated BRCA1 in the control of transcriptional regulation. BRCA1 has an N-terminal ring ®nger domain and a C-terminal transcription activation domain that activates transcription when linked to a DNA-binding domain (Chapman and Verma, 1996) . It has been shown that BRCA1 may interact with RNA helicase (Anderson et al., 1998) , and the transcriptional regulators p53 (Ouchi et al., 1998; Zhang et al., 1998) and c-Myc (Wang et al., 1998) . Transient transfection of BRCA1 expression vector results in transcriptional activation of the p21 promoter via both p53-dependent and -independent pathways (Somasundaram et al., 1997) . Recent ®nding by Harkin et al. has demonstrated that overexpression of BRCA1 induces endogenous GADD45 mRNA, leads to the JNK/SAP-dependent apoptosis (Harkin et al., 1999) . This evidence suggests that GADD45 should be one of BRCA1-targeted genes and might play a role in mediating BRCA1's biological functions. However, the mechanism by which BRCA1 induces GADD45 mRNA remains unclear.
GADD45 is a genotoxic stress-responsive gene and is induced by a variety of DNA damaging agents, such as UV radiation, methyl methanesulfonate (MMS) and ionizing radiation (IR) (Fornace et al., 1988; Papathanasiou et al., 1991) . In response to IR, GADD45 induction is regulated by the tumor suppressor p53 probably through the p53-binding motif located at the third intron of the GADD45 gene (Kastan et al., 1992; Zhan et al., 1994a) . Expression of Gadd45 protein suppresses cell growth in multiple tumor lines (Zhan et al., 1994b) . Gadd45 protein has been found to interact with PCNA (Smith et al., 1994) , p21 (Kearsey et al., 1995) , Cdc2 , core histone and MTK/MEKK4 (Takekawa and Saito, 1998) , indicating that GADD45 may be involved in multiple important cellular events. Most recently, GADD45 has been shown to play a role in the control of cell cycle G2-M checkpoint following certain DNA damaging treatments .
In the present study, we investigated the mechanism of how BRCA1 induces expression of GADD45 mRNA. When the GADD45 promoter was linked to a chloramphenical acetyltransferase (CAT) reporter gene and cotransfected with the BRCA1 expression vector into several human cell lines, we have found that GADD45 promoter, as measured by CAT activity, was strongly activated following BRCA1 expression. In contrast, BRCA1 does not activate c-Jun and c-fos promoters, which rule out a general eect of BRCA1 on all the immediate-responsive genes. Importantly, the induction of the GADD45 promoter by BRCA1 was shown to require the transcriptional properties of BRCA1 since either mutations or deletion of the transcriptional domain in BRCA1 protein abrogated the BRCA1 activation of the GADD45 promoter. The induction of GADD45 promoter by BRCA1 was not aected by the HPVE6 and the dominant-negative mutant p53, suggesting the BRCA1-mediated activation of the GADD45 promoter is p53-independent. Furthermore, using the deletion analysis, the BRCA1 responsive-elements of the GADD45 promoter were mapped at the promoter region from 7121 to 775.
Results

BRCA1 strongly activates GADD45 promoter
To explore the mechanism(s) of how BRCA1 transcriptionally up-regulates GADD45 expression, we tested the eect of BRCA1 on activation of the GADD45 promoter. In the initial experiments, two GADD45 promoter reporter constructs (pHG45-CAT1 and pHG45-CAT2) were co-transfected with pCR3-BRCA1 (BRCA1) expression vector into human breast carcinoma MCF-7 or human colorectal carcinoma HCT116 cells and followed by the employment of CAT assay. As a control, pCMV-neo vector was included. As shown in Figure 1a , two GADD45 promoter CAT reporter constructs (pHG45-CAT1 that contains the GADD45 promoter region from 72256 to +144 and pHG45-CAT2 that contains the GADD45 promoter from 7909 to +144) were strongly activated following expression of BRCA1 in both cell lines. In contrast, pCMV-neo did not exhibit activating eect on the GADD45 promoter. To determine transfection eciency, 4 mg of GFP (green¯uorescence protein) expression vector was co-transfected with each tested plasmid. The expression of GFP protein indicated that transfection eciency is similar among dierent samples and the variations were seen less than 20%. To con®rm the activation of the GADD45 promoter by BRCA1 is speci®cally due to the BRCA1 transactivation activity, several constructs expressing the tumorderived BRCA1 mutants (P1749R and Y1853insA) and truncated mutant (D500 ± 1863 BRCA1) were employed. Those mutants are transactivation-de®cient. As a positive control, the pWW-CAT, a p21 promoter CAT reporter construct, was included in the experiments. In Figure 1b , mutants of BRCA1 lacking normal transactivation domain were de®cient in activating both the GADD45 and p21 promoters, indicating that the intact transcriptional capability of BRCA1 is required for the induction of the GADD45 promoter.
It should be noted here that there is a discrepancy between these results and the report by Harkin et al. (1999) . In Harkin's report, there was no activation of the GADD45 proximal promoter (from 7994 to +1) by expression of BRCA1. Therefore, we constructed two GADD45 promoter CAT reporters spanning 7994 to +1 and 7909 to +1, and tested them in four dierent cell lines including MCF-7, H1299, HCT116 and Hela. Similarly, the proximal promoter CAT reporters were strongly activated by BRCA1 and results were shown in Figure 1c . In agreement with Harkin's observation that intron 3 of GADD45 was BRCA1-responsive, we found REX5, which contains ®ve copies of a p53 consensus that is identical to GADD45 intron 3, was activated following BRCA1 expression. In our experiments, the GADD45 promoter seems to be more potent in mediating BRCA1-dependent transcriptional activation compared to the intron 3 element of GADD45 ( Figure 1b) .
We next examined whether introduction of BRCA1 expression vector into human cells induces the expression of endogenous GADD45 mRNA. To do that, BRCA1 and pCI Tac expression vectors were cointroduced into MCF-7. Thirty-six hours later, Tacpositive cells were isolated for RNA analysis. As shown in Figure 1d , using RNase protection assay, the levels of endogenous GADD45 mRNA were found to evidently elevate in MCF-7 cells. Taken together, these results indicate that induction of GADD45 mRNA by BRCA1 is mediated through the transcriptional activation of GADD45 promoter following BRCA1 expression and activation of the GADD45 promoter depends on normal transcriptional function of BRCA1.
BRCA1 activates GADD45 promoter in a p53-independent manner
In cellular response to DNA damaging agents, GADD45 induction by ionizing radiation (IR) strictly depends on normal cellular p53 function (Kastan et al., 1992; Zhan et al., 1994a) . However, following exposure to certain non-IR agents such as UV irradiation and MMS, p53 is not required for the GADD45 induction but p53 can greatly contribute to those cellular responses . To test whether activation of the GADD45 promoter by BRCA1 involves normal p53 function, several human lines with known p53 status were utilized. pHG45-CAT2 plasmid was transfected into MCF-7 that contains wt p53 and its isogenic line, MCF7-E6 where HPV16-E6 is stably integrated and much of the p53's biological function has been abrogated. As shown in Figure 2a , BRCA1 was shown to strongly activate pHG45-CAT2 Figure 1 Activation of the GADD45 promoter following expression of BRCA1. (a) 4 mg of the GADD45 promoter CAT reporter constructs (pHG45-CAT1 and pHG45-CAT2) were cotransfected with 4 mg of either pCR3.BRCA1 (BRCA1) and pCMV´neo expression vectors into MCF-7 and HCT116 cells via the calcium phosphate method. Forty-eight hours later, cells were collected for the CAT assay (see Materials and methods). To determine transfection eciency, 4 mg of GFP (green¯uorescence protein) expression vector was co-transfected with each tested plasmid and the expression of GFP protein was detected as the internal control of transfection. (b) pHG45-CAT2, pWW-CAT (p21 promoter reporter construct) and REX5 (a reporter construct that contains ®ve copies of a p53 consensus that is identical to GADD45 intron 3) were transfected with the BRCA1 mutants of lacking transactivation activity into HCT116 cells. The CAT assays were performed as in (a). (c) The activating eect of BRCA1 on the GADD45 proximal promoter. pHG45-CAT23 (+1 to 7909 bp upstream of transcriptional start site) and pHG45-CAT30 (containing the region from +1 to 994) were co-transfected with the BRCA1 expression vector into MCF-7 and HCT116 cells. The CAT assays were carried out as in (a). (d) MCF-7 cells were transfected with 1 mg of pcI Tac and either 10 mg of pCMV´neo (lane 2) or pCR3´BRCA1 (lane 4). The Tac-positive cells were isolated. 10 mg of whole-cell RNA were hybridized with the human GADD45 and GAPD RBI-probes by RNase protection assay (see Materials and methods). As a positive control, an RNA sample from MCF-7 cells treated with MMS at 100 mg/ml for 4 h was included (lane 3)
BRCA1 activation of the GADD45 promoter S Jin et al in both MCF-7 and MCF7-E6 lines. Expression of E6 protein did not attenuate the induced-CAT activity of pHG45-CAT2 following BRCA1 expression. In support of these ®ndings, pHG45-CAT2 was also strongly responsive to BRCA1 expression in human H1299 cells, which have a deletion of endogenous p53. Similarly, when the E6 or the dominant-negative mutant p53 expression vectors were transiently cotransfected into MCF-7 cells with pHG45-CAT2, induction by BRCA1 remained unchanged (see Figure  2b ). In contrast, activation of PG-13, a p53 reporter construct, by p53 was abrogated following expression of E6 and mutant p53 proteins. Therefore, the results indicate that activation of GADD45 promoter by BRCA1 does not require normal cellular p53 function.
To further determine the transactivation of the GADD45 promoter by BRCA1 is a speci®c eect rather than a general eect on the stress-responsive genes, c-Jun and c-fos promoter CAT reporter constructs were cotransfected with BRCA1 expression vector and the CAT assay was followed to measure CAT activity. In Figure 2c , overexpression of BRCA1 protein did not activate the c-Jun and c-fos promoter although these two genes are induced in response to a Figure 2 Induction of the GADD45 promoter by BRCA1 is p53-independent. (a) pHG45-CAT2 was cotransfected with pCR3´BRCA1 into MCF-7, MCF7-E6 (with stable integration of HPVE6 gene) and H1299 cells, which has deletions of the p53 gene. The CAT assay was performed as in Figure 1 . (b) pHG45-CTA2 or PG-13 (p53 reporter construct) were cotransfected with the indicated plasmids into MCF-7 cells and the CAT assays were followed 40 h post-transfection. (c) The c-Jun, c-fos, actin and MEKK1 (an activator of JNK and p38 kinase) promoter CAT reporter constructs were cotransfected with the pCR3.BRCA1 expression vector into MCF-7 cells as in (a). The CAT activities were measured as described in Materials and methods variety of genotoxic stress agents that also activate GADD45 expression. In contrast, the c-fos-CAT and Jun-CAT reporter constructs were activated by protein expression of MEKK1, an activator of JNK and p38 kinase. Again, BRCA1 had no eect on the actin promoter. Therefore, BRCA1 expression is not generally associated with the activation of other stressinduced gene promoters, such as c-Jun and c-fos.
Mapping of BRCA1-responsive region in the GADD45 promoter
In order to localize the control elements involved in activation of the GADD45 promoter by BRCA1, analysis of the human GADD45 promoters with dierent 5'-deletions was undertaken. As shown in Figure 3a , the longest promoter, pHG45-CAT1, was strongly responsive to expression of BRCA1. With progressive 5' deletions, induction of the GADD45 promoter did not change substantially until the last construct, pHG45-CAT3, which extended 5' to 774 relative to the transcription start site. With this minimal promoter, expression of BRCA1 had little eect. Since the pHG45-CAT11, which contains the promoter region spanning from 7121 to +144, still showed strong induction by BRCA1, the region between 7121 and 775 may contain the major controlling elements required for responsiveness to the expression of BRCA1. Interestingly, all GADD45 promoter deletion constructs presented similar patterns of induction by BRCA1 in both MCF7 and H1299 cell lines. To further determine if the region between 7121 and 775 was required for induction of the GADD45 promoter by BRCA1, similar experiments were carried out with a reporter construct containing a deletion from 7121 to 775. When this region was deleted in pHG45-CAT2ma, BRCA1-induction of the GADD45 promoter was markedly reduced and more than 70% of the eect was lost compared to that of pHG45-CAT2 (Figure 3b) .
We next used a labeled double-strand oligonucleotide corresponding to the sequence between 7121 and 771 of the GADD45 promoter for EMSAs. Although one speci®c prominent DNA-protein complex was observed, we were unable to demonstrate BRCA1 protein directly binding to the promoter using a supershift assay (results not shown). These results suggest that BRCA1 regulation of the GADD45 promoter might not involve a direct binding of BRCA1 protein to the promoter. Figure 3 Mapping of the promoter region that contains the BRCA1-responsive elements. (a) Localization of the BRCA1-responsive element in the GADD45 promoter. 4 mg of the CAT reporter constructs containing the indicated regions of the GADD45 promoter were cotransfected with pCR´BRCA1 into MCF-7 and H1299 cell lines. The CAT assay was carried out as in Figure 1a. (b) pHG45-CAT2ma, in which the promoter sequence from 7121 to 775 was deleted, was cotransfected with the BRCA1 expression vector and the CAT activities were measured as in Figure 1a . The assays were at least conducted three times but only the representative experiment is shown here BRCA1 activation of the GADD45 promoter S Jin et al
Discussion
In this report, we have analysed the eect of BRCA1 on activation of the human GADD45 promoter in several human cell lines. We found that expression of wild type BRCA1 strongly activates the human GADD45 promoter, while the BRCA1 mutants of lacking transcriptional activity failed to induce the GADD45 promoter. Activation of GADD45 by BRCA1 is in a p53-independent manner and this activation is not due to the BRCA1-induced general eect on the stress-inducible genes since BRCA1 does not activate cjun and c-fos promoters. Using the 5'-deletion analyses, the region of the GADD45 promoter between 7121 to 775 was found to associate with the BRCA1-regulatory elements. Deletion of this region substantially abrogated the BRCA1-activation of the GADD45 promoter. Therefore, our ®ndings have demonstrated that the mechanism by which BRCA1 induces GADD45 mRNA is through the transactivation of the GADD45 promoter. Theses evidence further support the observation that GADD45 may act as one of the BRCA1-downstream genes. Inherited mutations in the BRCA1 gene are associated with high risk of developing breast cancer Ford and Easton, 1995; Miki et al., 1994) . A number of studies have linked BRCA1 to tumor growth suppression (Rao et al., 1996) , apoptosis, DNA repair, transcriptional regulation and the control of cell cycle progression (Anderson et al., 1998; Chapman and Verma, 1996; Gowen et al., 1998; Scully et al., 1997; Somasundaram et al., 1997) . Inactivation of BRCA1 has been found to correlate with genomic instability (Shen et al., 1998) . Much eort has been put on exploring the mechanism(s) of how BRCA1 participates in these important biological events. Recent report by Harkin et al. (1999) demonstrated that expression of BRCA1 induces GADD45 mRNA. This indicated that the biological roles for BRCA1 as a tumor suppressor might be mediated at least in part through its downstream genes, such as p21 and GADD45. It has been shown that GADD45 can be induced by a variety of DNA damaging agents and is regulated by the tumor suppressor p53. A number of studies have suggested that GADD45 be involved in the processes of apoptosis, DNA repair and signaling pathway (Smith et al., 1994 Takekawa & Saito, 1998) . Recently, Gadd45 protein has implicated in the control of cell cycle G2-M checkpoint via the inhibition of Cdc2/cyclin B1 kinase activity Zhan et al., 1999) . Therefore, it is postulated that GADD45 might be also able to mediate the role of BRCA1 in the control of cell cycle progression, whose disruption leads to genomic instability and tumorigenesis.
In the initial promoter-mapping work, the promoters employed in our CAT reporter constructs extend 3' to +144 relative to the transcription start site. However, in Harkin's report (Harkin et al., 1999) , the authors did not observe activation of the GADD45 promoter by BRCA1 when using the promoter region from 7994 to +1. For this reason, we further constructed two more promoter reporters, which contain the regions from 7994 to +1 and 7994 to +144. Both reporters showed strong activation following the expression of BRCA1 in four dierent human cell lines. This could be due to the dierence in cell types tested because we also did not observe signi®cant activation of the GADD45 promoter by BRCA1 in U2OS cells, which were used in Harkin's report (results not shown). Therefore, it can be assumed that there might be certain inhibitory factors existing in U2OS cells or lack of some mediating-factors, which are required for BRCA1 transactivation, in those cells. We have also identi®ed that the 5' region from 7121 to 775 is required for the BRCA1-mediated activation of the GADD45 promoter. Deletion of this region remarkably reduced the induction of GADD45 by BRCA1. Interestingly, this region has been recently found to contain the important DNA-damage responsive elements (paper in preparation). Therefore, the results indicate that the region between 7121 and 775 plays a crucial role in the regulation of the GADD45 gene in response to either DNA damage or growth arrest signals. Analysis of DNA sequence shows that there are two known transcriptional binding sites (Oct-1 and CAAT box) in this region. To our knowledge there is currently no report to demonstrate that BRCA1 can physically associate with the proteins binding to these two sites. The future study will be focused on the dissection of this region in order to characterize the speci®c responsive elements regulated by BRCA1.
The precise molecular and biochemical mechanisms of how BRCA1 activates the GADD45 promoter require further investigation. At the current time, BRCA1 has not been well characterized as a DNAbinding transcription factor. In our EMSA experiments, we were unable to demonstrate BRCA1 directly binding to the GADD45, but we were able to detect Oct-1 protein binding to this region in a supershift assay (results not shown). Therefore, it can be speculated that BRCA1 might activate the GADD45 promoter probably through its interaction with another protein(s) that directly binds to the GADD45 promoter. The interactions between the BRCA1 and the third protein(s) might also involve more complex signal transduction cascade. The similar observation has been obtained in our previous report. In it, p53 has been found to participate in the transcriptional induction of the GADD45 promoter through its interaction with WT1 protein that is a transcription factor and directly binds to GADD45 promoter (Zhan et al., 1998) . In addition, the post-translational modi®cation, such as phophorylation and acetylation, of BRCA1 and its interactions with transcriptional co-activators might also be involved in the regulation of GADD45 promoter. Taken all together, this study has further con®rmed the BRCA1-GADD45 pathway and provided the insight into the understanding of how BRCA1 regulates it downstream genes as well.
Materials and methods
Plasmid clones
The following plasmid constructs were used: pHG45-CAT1, constructed by inserting the SalI-SmaI fragment of GADD45 promoter spanning 72256 to +144 relative to the transcription start site into pCAT-Basic (promega); pHG45-CAT2, similarly constructed by inserting the HindIII-SmaI fragment of GADD45 promoter from 7909 to +144 into pCAT-Basic (Zhan et al., 1998) . pHG-CAT23 was constructed by inserting the fragment of the GADD45 promoter from 994 to +1 into pCAT-Basic. Dr Weber provided pCR3-BRCA1, a construct expressing wt human BRCA1 protein, and BRCA1 mutants including pCR3-BRCA1 1749R , pCR3-BRCA1 1853insA and pCR3-BRCA1 D500 ± 1863 (Somasundaram et al., 1997; Thakur et al., 1997) . Dr Vogelstein provided pC53-SCX3, which expresses a dominant-negative mutant p53 protein containing a substitution of Ala for Val-143 and PG-13, which contains 13 repeats of a p53-binding site inserted 5' to the polyomavirus promoter linked to a CAT report construct (Kern et al., 1992) . pCMV-E6 expresses human HPVE6 protein and has been shown to block p53 function (Kessis et al., 1993) . c-fos-CAT was described as previously (Zhan et al., 1998) . Dr Ashwell provided Tac the Tac expression vector pCI.
Cell lines, tissue culture and transfection
The human breast carcinoma MCF-7 line and its subline MCF7-E6, the human lung carcinoma line H1299 and the human colorectal carcinoma line HCT116 were grown in F12 medium supplemented with 10% fetal bovine serum. The cells were transfected by the calcium phosphate (Zhan et al., 1993) . In these experiments, 4 mg of the GADD45 promoter reporter constructs and 4 mg of indicated expression vectors were cotransfected into human cells. Forty hours later, cells were collected for the CAT assay. In addition, 4 mg of pCMV-GFP plasmid (which contains green¯uorescence protein) was included in each experiment. After transfection, expression of GFP protein is detected by Western blotting assay to determine transfection eciency.
For RNase protection analysis, 10 mg of either pCR3-BRCA1 or pCMV.neo were co-transfected into MCF-7 with 1.0 mg of pCI Tac, a cell surface protein expression vector, by the lipofectamine method. Forty-eight hours after transfection, cells were harvested and washed once with cold medium. Dynabeads (Dyna, Lake Success, NY, USA) coated with anti-Tac antibody were added to the cells and incubated with gentle rotation at 48C for 2 h. The Tacpositive cells were isolated magnetically, washed once with buer saline, and then lysed for the RNA protection assay.
CAT assay
Measurement of CAT activity was carried out as described previously (Zhan et al., 1993) . Cells were collected and resuspended in 0.25 M TRIS (pH 7.8). Cells were disrupted by three cycles of freeze-thaw. The equal amounts of protein were used for each CAT assay. The CAT reaction mixture was incubated at 378C overnight and the CAT activity was determined by measuring the acetylation of 14 C-labeled chloramphenicol by the thin-layer chromatography. Radioactivity was measured directed with Betascope analyser. The speci®c CAT activity was calculated by determining the fraction of chloramphenicol that had been acetylated. The relative CAT activity was determined by normalizing the activity of the treated samples to that of the untreated sample. Each value represented the average of at least three separate determinations.
RNA isolation and RNAase protection assay
Cells were lysed in 4 M guanidine thiocynate and total cellular RNA was isolated by the acid phenol method. For RNAase protection assay, the plasmids pRibo-Hg45 and pGAPD were linearized with HindIII or BamH1 and in vitro transcription was carried out at 48C with T3 or T7 RNA polymerases. GADD45 and GAPD riboprobes were labeled with [a-32 P]UTP. Ten mg of whole cellular RNA was hybridized with both riboprobes simultaneously in the same test tube at 538C for 15 h and then digested with RNAase. Following protease K digestion and pheno-chloroform extraction, the samples were analysed on an 8 M urea, 5% acrylamide gel. Protected bands were visualized by autoradiography and were quantitated with a Phosphoimager analyser.
EMSA
Nuclear extracts were prepared and an electrophoretic mobility shift assay (EMSA) was carried out as described previously (Zhan et al., 1998) . DNA binding reactions were performed for 10 min at room temperature in a binding buer containing 20 mM HEPES (pH 7.8), 150 mM NaCl, 1 mM dithiothreitol, 1 mg of poly(dIdC), 10% glycerol and 20 mg of nuclear protein. 4610 4 d.p.m. of labeled probe. The probe was a 50-mer double stranded synthetic oligonucleotide containing the region spanning 7121 to 771 of the GADD45 promoter. Each strand was labeled separately and the strands were annealed, then puri®ed by G-25 column. The samples were analysed on a 4% non-denaturing acrylamide gel (Zhan et al., 1998) .
